
## Monica Patten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8019430/publications.pdf Version: 2024-02-01



Μονίς Α Ράττεν

#	Article	IF	CITATIONS
1	A Novel miRNA Screen Identifies miRNA-4454 as a Candidate Biomarker for Ventricular Fibrosis in Patients with Hypertrophic Cardiomyopathy. Biomolecules, 2021, 11, 1718.	4.0	14
2	Association of Asymmetric Dimethylarginine and Diastolic Dysfunction in Patients with Hypertrophic Cardiomyopathy. Biomolecules, 2019, 9, 277.	4.0	8
3	The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy. Clinical Research in Cardiology, 2018, 107, 130-137.	3.3	11
4	Early segmental relaxation abnormalities in hypertrophic cardiomyopathy for differential diagnostic of patients with left ventricular hypertrophy. Clinical Cardiology, 2017, 40, 1026-1032.	1.8	6
5	Early Detection of Symptomatic Paroxysmal Cardiac Arrhythmias by Transâ€Telephonic ECG Monitoring: Impact on Diagnosis and Treatment of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2016, 27, 1032-1037.	1.7	9
6	Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy. Journal of Cardiac Failure, 2016, 22, 845-850.	1.7	31
7	Orthostatic Blood Pressure Test for Risk Stratification in Patients with Hypertrophic Cardiomyopathy. PLoS ONE, 2015, 10, e0131044.	2.5	0
8	Event-Recorder Monitoring in the Diagnosis of Atrial Fibrillation in Symptomatic Patients: Subanalysis of the SOPAT Trial. Journal of Cardiovascular Electrophysiology, 2006, 17, 1216-1220.	1.7	87
9	Suppression of paroxysmal atrial tachyarrhythmias ? results of the SOPAT trial. European Heart Journal, 2004, 25, 1395-1404.	2.2	147